ECM-PCL Composite Scaffold for Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone scaffolds either lack bioactivity or are difficult to manufacture in large, clinically relevant sizes, with synthetic scaffolds being bioinert and naturally-derived scaffolds facing challenges in geometry and batch-to-batch variability.
Innovation Solution
A composite scaffold made by combining decellularized trabecular bone particles with a biocompatible polymer like polycaprolactone (PCL) using 3D printing, which incorporates the osteoinductive and osteoconductive properties of native bone while allowing for anatomically shaped and complex geometries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If purely synthetic materials (e.g., polycaprolactone) are used for bone scaffolds, then ease of manufacture and geometric control are improved, but bioactivity is lost
Solution Approach 1:
The patent combines synthetic polycaprolactone (PCL) polymer with natural decellularized bone extracellular matrix (ECM) particles to create a composite scaffold material. The PCL provides structural integrity and manufacturability, while the ECM particles contribute bioactivity including osteoinductive and osteoconductive properties. This composite approach resolves the contradiction by integrating both synthetic and natural material benefits in a single scaffold system.
2Reliability
If purely natural materials (e.g., decellularized trabecular bone) are used for bone scaffolds, then bioactivity is improved, but manufacturing complexity and batch variability increase
Solution Approach 1:
The synthetic PCL polymer acts as an intermediary matrix that encapsulates and stabilizes the natural ECM particles. This intermediary structure provides a consistent, controllable framework that reduces batch-to-batch variability inherent in purely natural materials, while still preserving the bioactive ECM components. The PCL-ECM composite thus mediates between the need for natural bioactivity and manufacturing consistency.
3Volume of moving object
If large, clinically-sized scaffolds are manufactured, then volume and clinical applicability are improved, but structural integrity and consistency deteriorate
Solution Approach 1:
The patent utilizes 3D printing technology to precisely control fabrication parameters such as layer thickness, pore size, and material deposition rates during scaffold manufacturing. By optimizing these parameters, the process can produce large-volume scaffolds with consistent internal architecture and structural integrity. The controlled parameter changes enable scaling to clinical sizes while maintaining manufacturing precision through digital modeling and automated fabrication.
Data Source
AI summary
An extracellular matrix (ECM) mixture and ECM scaffolds made with same are disclosed. The ECM mixture can comprise from about 5% to about 85% by weight of ECM material and from about 15% to about 95% by weight of a polymer material, such as, but not limited to, a biodegradable polyester. The presently disclosed anatomically-shaped porous ECM scaffolds can be formed, for example, using a three-dimensional (3D) printing process, an injection molding process, or any other process.